{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:21:07Z","timestamp":1767900067902,"version":"3.49.0"},"reference-count":54,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Humanitarian Foundation of the Swiss Red Cross","award":["Nr. 266"],"award-info":[{"award-number":["Nr. 266"]}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Viruses"],"abstract":"<jats:p>The blood donor population has great potential to serve as a sentinel system for the general population. The data presented in this study of a survey of the seroprevalence of Anti-SARS-CoV-2 antibodies in Switzerland are an illustrative example of this possibility. From March 2020 to January 2021, the increase in antibody seroprevalence for both Anti-NCP and Anti-S was only very moderate, up to ~17%. In May\/June 2021, the Anti-NCP seroprevalence was 21.6% and the S-seroprevalence 59.4%, respectively, indicating only a moderate natural infection rate. The Anti-seroprevalence rate was in good agreement with the first vaccination campaign launched in winter 2020\/21. The dramatic increase in the antibodies against the NCP protein (74.6%) since November\/December 2021 to June\u2013August 2022 was simultaneous with the appearance and rapid spread of the Omicron SARS-CoV-2 variant in Switzerland and the abolition of compulsory mask wearing in public spaces. At the end of 2022, 99.0% of the blood donor population already developed antibodies against the S protein and 83.9% against the NCP. One year later, after the official termination of the pandemic, these seroprevalences were even higher, 99.8% for the Anti-S and 95.0% for Anti-NCP. This increase for both of them was in accordance with the vaccination campaigns, the abolition of mask wearing, and the spread of the Omicron variant. These data show how the blood donor population can be used to represent the infection surveillance of the general population of a region or country.<\/jats:p>","DOI":"10.3390\/v17101292","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T09:43:12Z","timestamp":1758706992000},"page":"1292","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-SARS-CoV-2 Antibody Development over Four Years in Blood Donors"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3142-7616","authenticated-orcid":false,"given":"Christoph","family":"Niederhauser","sequence":"first","affiliation":[{"name":"Interregional Blood Transfusion SRC, 3008 Bern, Switzerland"},{"name":"Institute of Infectious Diseases, University of Bern, 3001 Bern, Switzerland"},{"name":"Faculty of Biological Medicine, Lausanne University Hospital, 1005 Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadja","family":"Widmer","sequence":"additional","affiliation":[{"name":"Interregional Blood Transfusion SRC, 3008 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Tinguely","sequence":"additional","affiliation":[{"name":"Interregional Blood Transfusion SRC, 3008 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Suter Riniker","sequence":"additional","affiliation":[{"name":"Institute of Infectious Diseases, University of Bern, 3001 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Fontana","sequence":"additional","affiliation":[{"name":"Interregional Blood Transfusion SRC, 3008 Bern, Switzerland"},{"name":"Faculty of Biological Medicine, Lausanne University Hospital, 1005 Lausanne, Switzerland"},{"name":"Blood Transfusion Service SRC Della Svizzera Italiana, 6900 Lugano, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7942-6746","authenticated-orcid":false,"given":"Andreas","family":"Buser","sequence":"additional","affiliation":[{"name":"Blood Transfusion Service SRC Beider Basel, 4031 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Waldvogel","sequence":"additional","affiliation":[{"name":"Blood Transfusion Service SRC Gen\u00e8ve, 1211 Gen\u00e8ve, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jutta","family":"Thierbach","sequence":"additional","affiliation":[{"name":"Blood Transfusion Service SRC Nordostschweiz, 9000 St. Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Z\u00fcger","sequence":"additional","affiliation":[{"name":"Blood Transfusion Service SRC Thurgau, 8500 Frauenfeld, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Gowland","sequence":"additional","affiliation":[{"name":"Interregional Blood Transfusion SRC, 3008 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"w20271","DOI":"10.4414\/smw.2020.20271","article-title":"Reproductive number of the COVID-19 epidemic in Switzerland with a focus on the Cantons of Basel-Stadt and Basel-Landschaft","volume":"150","author":"Scire","year":"2020","journal-title":"Swiss Med. Wkly."},{"key":"ref_2","unstructured":"Mathieu, E., Ritchie, H., Rod\u00e9s-Guirao, L., Appel, C., Gavrilov, D., Giattino, C., Hasell, J., Macdonald, B., Dattani, S., and Beltekian, D. (2024, December 15). COVID-19 Pandemic. Available online: https:\/\/ourworldindata.org\/coronavirus."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Riguzzi, M., and Gashi, S. (2021). Lessons From the First Wave of COVID-19: Work-Related Consequences, Clinical Knowledge, Emotional Distress, and Safety-Conscious Behavior in Healthcare Workers in Switzerland. Front. Psychol., 12.","DOI":"10.3389\/fpsyg.2021.628033"},{"key":"ref_4","unstructured":"Coronavirus: Wichtige Entscheide des Bundesrats (2024, December 15). Federal Department of the Enviroment, Transport, Energy and Communications. Available online: https:\/\/www.uvek.admin.ch\/de\/coronavirus-wichtige-entscheide-des-bundesrats."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100547","DOI":"10.1016\/j.lanepe.2022.100547","article-title":"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: A population-based study","volume":"24","author":"Zaballa","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_6","first-page":"18","article-title":"Longitudinal humoral and cell-mediated immune responses in a population-based cohort in Zurich, Switzerland between March and June 2022\u2014Evidence for protection against Omicron SARS-CoV-2 infection by neutralizing antibodies and spike-specific T-cell responses","volume":"133","author":"Zens","year":"2023","journal-title":"Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis."},{"key":"ref_7","first-page":"2200561","article-title":"Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022","volume":"27","author":"Amati","year":"2022","journal-title":"Euro Surveill. Bull. Eur. Sur Les Mal. Transm. Eur. Commun. Dis. Bull."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s15010-023-02011-0","article-title":"Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: A population-based study","volume":"51","author":"Tancredi","year":"2023","journal-title":"Infection"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JOM.0000000000002690","article-title":"SARS-CoV-2 Seroprevalence in Employees of Four Essential Non-Health Care Sectors at Moderate\/High Risk of Exposure to Coronavirus Infection: Data From the \u201cFirst Wave\u201d","volume":"65","author":"Belloni","year":"2023","journal-title":"J. Occup. Environ. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e28904","DOI":"10.1002\/jmv.28904","article-title":"Do quantitative levels of antispike-IgG antibodies aid in predicting protection from SARS-CoV-2 infection? Results from a longitudinal study in a police cohort","volume":"95","author":"Sendi","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"104880","DOI":"10.1016\/j.antiviral.2020.104880","article-title":"Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors","volume":"181","author":"Gallian","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1038\/s41467-020-19481-7","article-title":"Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands","volume":"11","author":"Slot","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_13","first-page":"2001285","article-title":"SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020","volume":"25","author":"Fischer","year":"2020","journal-title":"Euro Surveill. Bull. Eur. Sur Les Mal. Transm. Eur. Commun. Dis. Bull."},{"key":"ref_14","first-page":"181","article-title":"SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan","volume":"19","author":"Valenti","year":"2021","journal-title":"Blood Transfus. Trasfus. Del Sangue"},{"key":"ref_15","first-page":"263","article-title":"Blood donor serological screening for SARS-CoV-2 as a tool to estimate the prevalence of asymptomatic infection in a low-intermediate endemic area of southern Italy after the first wave of the pandemic","volume":"20","author":"Russo","year":"2022","journal-title":"Blood Transfus. Trasfus. Del Sangue"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100479","DOI":"10.1016\/j.lanepe.2022.100479","article-title":"Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study","volume":"21","author":"Erikstrup","year":"2022","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_17","first-page":"353","article-title":"SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain)","volume":"20","author":"Piron","year":"2022","journal-title":"Blood Transfus. Trasfus. Del Sangue"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Offergeld, R., Preu\u00dfel, K., Zeiler, T., Aurich, K., Baumann-Baretti, B.I., Ciesek, S., Corman, V.M., Dienst, V., Drosten, C., and G\u00f6rg, S. (2023). Monitoring the SARS-CoV-2 Pandemic: Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in Germany-Results from the SeBluCo Study 2020\u20132022. Pathogens, 12.","DOI":"10.3390\/pathogens12040551"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s40121-021-00504-9","article-title":"Multicentre Performance Evaluation of the Elecsys Anti-SARS-CoV-2 Immunoassay as an Aid in Determining Previous Exposure to SARS-CoV-2","volume":"10","author":"Riester","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_20","unstructured":"FOPH (2022). Coronavirus: Federal Council to Lift Measures\u2014Mask Requirement on Public Transport and in Healthcare Institutions and Isolation in the Event of Illness to Remain Until End of March, The Swiss Federal Council. Available online: https:\/\/www.news.admin.ch\/en\/nsb?id=87216."},{"key":"ref_21","unstructured":"(2022). Coronavirus: Federal Council Lifts Requirements to Quarantine and to Work from Home and Launches Consultation on a Widespread Easing of Measures, Federal Department of the Environment, Transport, Energy and Communications. Available online: https:\/\/www.uvek.admin.ch\/en\/nsb?id=87041."},{"key":"ref_22","unstructured":"(2020). Swissmedic Grants Authorisation for the first COVID-19 Vaccine in Switzerland: Vaccine from Pfizer\/BioNTech Authorised in the Rolling Review Procedure After Close Scrutiny of the Risks and Benefits, Swiss Agency for Therapeutic Products. Available online: https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/news\/coronavirus-covid-19\/covid-19-impfstoff_erstzulassung.html."},{"key":"ref_23","unstructured":"(2021). Swissmedic Grants Authorisation for the COVID-19 Vaccine from Moderna, Swiss Agency for Therapeutic Products. Available online: https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/news\/coronavirus-covid-19\/zulassung-covid-19-impfstoff-moderna.html#:~:text=The%20establishment%20licence."},{"key":"ref_24","unstructured":"(2023). COVID-19 Switzerland: Vaccinations, Switzerland and Liechtenstein, Federal Office of Public Health FOPH. Available online: https:\/\/www.covid19.admin.ch\/en\/vaccination\/persons?geo=CH."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"114271","DOI":"10.1016\/j.jviromet.2021.114271","article-title":"Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay","volume":"297","author":"Riester","year":"2021","journal-title":"J. Virol. Methods"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/ije\/29.2.362","article-title":"Ten years of serological surveillance in England and Wales: Methods, results, implications and action","volume":"29","author":"Osborne","year":"2000","journal-title":"Int. J. Epidemiol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Surendra, H., Ahmad, R.A., Kusumasari, R.A., Rahayujati, T.B., Damayanti, S.Y., Tetteh, K.K.A., Chitnis, C., Stresman, G., and Cook, J. (2020). Using health facility-based serological surveillance to predict receptive areas at risk of malaria outbreaks in elimination areas. BMC Med., 18.","DOI":"10.1186\/s12916-019-1482-7"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/infdis\/jiy137","article-title":"Benefits and Challenges in Using Seroprevalence Data to Inform Models for Measles and Rubella Elimination","volume":"218","author":"Winter","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3201\/eid2407.171928","article-title":"Integrated Serologic Surveillance of Population Immunity and Disease Transmission","volume":"24","author":"Arnold","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/23744235.2021.2003856","article-title":"Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: Evidence for asymptomatic young donors as potential virus spreaders","volume":"54","author":"Antonucci","year":"2022","journal-title":"Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.11606\/s1518-8787.2020054002643","article-title":"Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil","volume":"54","author":"Szwarcwald","year":"2020","journal-title":"Rev. De Saude Publica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41467-021-21503-x","article-title":"The prevalence of antibodies to SARS-CoV-2 among blood donors in China","volume":"12","author":"Chang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1126\/science.abe1916","article-title":"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors","volume":"371","author":"Uyoga","year":"2021","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/vox.13100","article-title":"An international comparison of anti-SARS-CoV-2 assays used for seroprevalence surveys from blood component providers","volume":"116","author":"Lewin","year":"2021","journal-title":"Vox Sang."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"104578","DOI":"10.1016\/j.jcv.2020.104578","article-title":"Comparison of the analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated molecular assays","volume":"130","author":"Mostafa","year":"2020","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"105928","DOI":"10.1016\/j.isci.2023.105928","article-title":"Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region","volume":"26","author":"Emmenegger","year":"2023","journal-title":"iScience"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s10096-022-04448-x","article-title":"Rapid increase in SARS-CoV-2 seroprevalence during the emergence of Omicron variant, Finland","volume":"41","author":"Ahava","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_38","unstructured":"(2024, December 15). COVID-19 Switzerland: Information on the Current Situation, as of 28 November 2023, Available online: https:\/\/www.covid19.admin.ch\/en\/overview."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/ije\/dyad098","article-title":"Development of hybrid immunity during a period of high incidence of Omicron infections","volume":"52","author":"Frei","year":"2023","journal-title":"Int. J. Epidemiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e01828-20","DOI":"10.1128\/JVI.01828-20","article-title":"Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies","volume":"95","author":"Fenwick","year":"2021","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"eabe0240","DOI":"10.1126\/sciimmunol.abe0240","article-title":"Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome","volume":"5","author":"Powell","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMc2025179","article-title":"Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild COVID-19","volume":"383","author":"Ibarrondo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/all.14622","article-title":"Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections","volume":"76","author":"Lei","year":"2021","journal-title":"Allergy"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1038\/s41467-022-32573-w","article-title":"Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort","volume":"13","author":"Menges","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e2109229118","DOI":"10.1073\/pnas.2109229118","article-title":"Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis","volume":"118","author":"Sah","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/22221751.2020.1729071","article-title":"Molecular and serological investigation of 2019-nCoV infected patients: Implication of multiple shedding routes","volume":"9","author":"Zhang","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_48","unstructured":"(2021). COVID-19 Impfquoten-Monitoring in Deutschland (COVIMO), Report No.: Report 6; Robert Koch Institute. Available online: https:\/\/www.rki.de\/DE\/Themen\/Infektionskrankheiten\/Impfen\/Forschungsprojekte\/abgeschlossene-Projekte\/COVIMO\/Downloads\/covimo_studie_bericht_6.pdf?__blob=publicationFile&v=1."},{"key":"ref_49","unstructured":"(2024, December 15). Swiss Transfusion Swiss Red Cross (SRC) Guidelines, Available online: https:\/\/dokuman.sbsc-bsd.ch\/de-de\/neuevorschriftenbsd\/vorschriftenbsd.aspx."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/vox.13374","article-title":"Research partnerships between blood services and public health authorities: An international, cross-sectional survey","volume":"117","author":"Lewin","year":"2022","journal-title":"Vox Sang."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1111\/trf.17140","article-title":"How do we decide how representative our donors are for public health surveillance?","volume":"62","author":"Drews","year":"2022","journal-title":"Transfusion"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S1473-3099(20)30631-9","article-title":"SeroTracker: A global SARS-CoV-2 seroprevalence dashboard","volume":"21","author":"Arora","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_53","unstructured":"(2024, December 15). SeroTracker: Dashboard and Data Platform for SARS-CoV-2 Serosurveys [Internet]. Available online: https:\/\/www.serotracker.com\/pathogen\/sarscov2\/dashboard."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Bergeri, I., Whelan, M.G., Ware, H., Subissi, L., Nardone, A., Lewis, H.C., Li, Z., Ma, X., Valenciano, M., and Cheng, B. (2022). Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. PLoS Med., 19.","DOI":"10.1371\/journal.pmed.1004107"}],"updated-by":[{"DOI":"10.3390\/v17111447","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000}}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/10\/1292\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:22:44Z","timestamp":1762176164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/10\/1292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":54,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["v17101292"],"URL":"https:\/\/doi.org\/10.3390\/v17101292","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]}}}